Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on March 31, 2017. The filing discloses the entry into a material definitive agreement to establish an "at the market" equity offering program.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the potential capital raise:
- Maximum Offering Size: Up to $5,000,000 in aggregate offering price.
- Commission Rate: 3.0% of gross proceeds per share sold.
Material Changes
On March 31, 2017, the Company entered into a Common Stock Sales Agreement with H.C. Wainwright & Co., LLC as the sales agent. This agreement authorizes the Company to sell shares of its common stock from time to time through the agent. The shares will be issued pursuant to a Registration Statement on Form S-3 originally filed on September 28, 2015.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use net proceeds for research related to product candidates, manufacturing, working capital, and general corporate purposes, which may include acquisitions or business combinations. The Company cannot specify all particular uses with certainty at this time.
Flexibility and Risks: The Company has no obligation to sell any shares and may suspend sales or terminate the agreement at any time. Sales may occur on the NASDAQ Capital Market or through other permitted methods. The filing includes standard legal disclaimers regarding the validity of the shares and state securities laws.
Investor Verification Checklist
- Verify the current market price of Capricor Therapeutics common stock to assess potential dilution from the $5,000,000 offering.
- Review the full text of the Common Stock Sales Agreement (Exhibit 10.1) for specific termination rights and sales restrictions.
- Confirm the status of the underlying Form S-3 Registration Statement to ensure it remains effective for the offering.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.